Mari D. Takashima, Areum Hyun, Sabrina de Souza, Victoria Gibson, Thiago Lopes Silva, Patricia Kuerten Rocha, Siriporn Vetcho, Jenna Nunn, Amanda J. Ullman
Background
Central venous access devices (CVADs) are crucial for treating children with cancer and blood disorders. However, international variations in CVAD practices may impact patient outcomes. This study aimed to explore current CVAD selection and insertion practices in paediatric cancer care globally.
Methods
An international cross-sectional survey was conducted among clinicians involved in CVAD insertion and management for paediatric cancer patients. Convenience snowball sampling was used with participants invited via established clinical trial networks and other associated networks. The survey explored CVAD selection, insertion techniques, and related practices across economic classifications (high-income vs. other-income [lower middle and higher middle income]).
Results
Of 300 respondents from 42 countries who completed the demographic section of the survey, 220 (73.3%) reported using CVADs in their practice. There were more respondents with no CVAD access in other-income countries (n = 25; 21.7%) compared to high-income countries (n = 8; 4.3%). PICCs were predominantly inserted by nurses in other-income countries (n = 30; 50.9%) versus anaesthetists (n = 49; 48%) and radiologists (n = 48; 47.1%) in high-income countries. Ultrasound guidance for PICC insertion was used less frequently in other-income countries (45.8% [n = 27] vs. 68.6% [n = 70]). Device selection generally aligned with guidelines, but variations existed, particularly for long-term use. Skin decontaminant choices also varied, with alternative formulations more common in other income countries.
Conclusions
This survey reveals global disparities in CVAD practices for paediatric cancer care. Resource availability appears to influence device selection, insertion techniques and insertion-related care practices. These findings highlight the need for context-specific guidelines and increased research participation from resource-limited settings to improve global equity in paediatric cancer care.
{"title":"Central Venous Access Device Selection and Insertion in Children With Blood Disorders and Cancer: An International Cross-Sectional Survey","authors":"Mari D. Takashima, Areum Hyun, Sabrina de Souza, Victoria Gibson, Thiago Lopes Silva, Patricia Kuerten Rocha, Siriporn Vetcho, Jenna Nunn, Amanda J. Ullman","doi":"10.1155/ecc/6671160","DOIUrl":"https://doi.org/10.1155/ecc/6671160","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Central venous access devices (CVADs) are crucial for treating children with cancer and blood disorders. However, international variations in CVAD practices may impact patient outcomes. This study aimed to explore current CVAD selection and insertion practices in paediatric cancer care globally.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>An international cross-sectional survey was conducted among clinicians involved in CVAD insertion and management for paediatric cancer patients. Convenience snowball sampling was used with participants invited via established clinical trial networks and other associated networks. The survey explored CVAD selection, insertion techniques, and related practices across economic classifications (high-income vs. other-income [lower middle and higher middle income]).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of 300 respondents from 42 countries who completed the demographic section of the survey, 220 (73.3%) reported using CVADs in their practice. There were more respondents with no CVAD access in other-income countries (<i>n</i> = 25; 21.7%) compared to high-income countries (<i>n</i> = 8; 4.3%). PICCs were predominantly inserted by nurses in other-income countries (<i>n</i> = 30; 50.9%) versus anaesthetists (<i>n</i> = 49; 48%) and radiologists (<i>n</i> = 48; 47.1%) in high-income countries. Ultrasound guidance for PICC insertion was used less frequently in other-income countries (45.8% [<i>n</i> = 27] vs. 68.6% [<i>n</i> = 70]). Device selection generally aligned with guidelines, but variations existed, particularly for long-term use. Skin decontaminant choices also varied, with alternative formulations more common in other income countries.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This survey reveals global disparities in CVAD practices for paediatric cancer care. Resource availability appears to influence device selection, insertion techniques and insertion-related care practices. These findings highlight the need for context-specific guidelines and increased research participation from resource-limited settings to improve global equity in paediatric cancer care.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11953,"journal":{"name":"European Journal of Cancer Care","volume":"2025 1","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/ecc/6671160","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145316960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Caterina Calderon, M. Mar Muñoz-Sánchez, Jesús Peña-López, M. Helena López-Ceballos, Ana Fernández-Montes, Elena Asensio-Martinez, Raúl Carrillo-Vicente, Marina Gustems, Paula Jimenez-Fonseca
Fatigue is a significant challenge for cancer patients, substantially affecting their quality of life, physical symptoms, and psychological distress. This study examined the relationship between fatigue in patients with advanced cancer and sociodemographic, clinical, and psychological factors. Conducted across 15 oncology departments in Spain, the study included patients with locally advanced, unresectable, or metastatic cancer eligible for systemic treatment. Participants completed the Fatigue Assessment Scale (FAS), European Organisation for Research and Treatment (EORTC QLQ-C30), Locus of Control (UWBHS), and Brief Symptom Inventory (BSI). A total of 512 patients are participated, classified into low-fatigue (55%) and high-fatigue (45%) groups. High fatigue was associated with lower educational attainment (53% vs. 44%), locally advanced disease (26% vs. 17%), poorer functional status according to ECOG (70% vs. 30%), and shorter expected survival (< 18 months: 51% vs. 37%). Additionally, patients with high fatigue reported greater use of integrative medicine (24% vs. 14%, p = 0.003) and higher prevalence of symptoms such as pain, nausea, and memory problems (p < 0.05). They also exhibited poorer quality of life and higher psychological distress. These findings highlight the need to develop multidimensional strategies that address both physical symptoms and quality of life to enhance the well-being of cancer patients. Clinically, systematic screening for fatigue and psychological distress, alongside tailored supportive interventions, should be embedded in routine care to optimize outcomes in advanced cancer patients.
{"title":"Fatigue, Physical Symptoms, Psychological Distress, and Use of Integrative Medicine in Patients With Advanced Cancer","authors":"Caterina Calderon, M. Mar Muñoz-Sánchez, Jesús Peña-López, M. Helena López-Ceballos, Ana Fernández-Montes, Elena Asensio-Martinez, Raúl Carrillo-Vicente, Marina Gustems, Paula Jimenez-Fonseca","doi":"10.1155/ecc/5527075","DOIUrl":"https://doi.org/10.1155/ecc/5527075","url":null,"abstract":"<p>Fatigue is a significant challenge for cancer patients, substantially affecting their quality of life, physical symptoms, and psychological distress. This study examined the relationship between fatigue in patients with advanced cancer and sociodemographic, clinical, and psychological factors. Conducted across 15 oncology departments in Spain, the study included patients with locally advanced, unresectable, or metastatic cancer eligible for systemic treatment. Participants completed the Fatigue Assessment Scale (FAS), European Organisation for Research and Treatment (EORTC QLQ-C30), Locus of Control (UWBHS), and Brief Symptom Inventory (BSI). A total of 512 patients are participated, classified into low-fatigue (55%) and high-fatigue (45%) groups. High fatigue was associated with lower educational attainment (53% vs. 44%), locally advanced disease (26% vs. 17%), poorer functional status according to ECOG (70% vs. 30%), and shorter expected survival (< 18 months: 51% vs. 37%). Additionally, patients with high fatigue reported greater use of integrative medicine (24% vs. 14%, <i>p</i> = 0.003) and higher prevalence of symptoms such as pain, nausea, and memory problems (<i>p</i> < 0.05). They also exhibited poorer quality of life and higher psychological distress. These findings highlight the need to develop multidimensional strategies that address both physical symptoms and quality of life to enhance the well-being of cancer patients. Clinically, systematic screening for fatigue and psychological distress, alongside tailored supportive interventions, should be embedded in routine care to optimize outcomes in advanced cancer patients.</p>","PeriodicalId":11953,"journal":{"name":"European Journal of Cancer Care","volume":"2025 1","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/ecc/5527075","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145316935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Eda So, Brianna Poirier, Madison Cachagee, Joanne Hedges, Lisa Jamieson, Sneha Sethi
Background
Psycho-oncology is a branch of research related to cancer care that focuses on the psychological, behavioural, spiritual, physical and social aspects of the cancer experience. Whilst psycho-oncology and its applications are relatively nascent, there is a paucity of research regarding the psycho-oncological considerations for Indigenous communities. Due to the deleterious impacts of colonisation, the burden of disease experienced amongst Indigenous Peoples is disproportionately higher than in non-Indigenous populations. Yet, the lack of attention paid towards the development of appropriate models of care fails to reflect this. Therefore, this systematic review aims to build an understanding of psycho-oncology for Indigenous Peoples, globally.
Methods
Two independent reviewers searched PubMed, Embase, Web of Science, PsychInfo and ProQuest using a pre-established search strategy. The search was not limited by geographic setting, language, age or gender. Qualitative studies with Indigenous participants that focused on the psychological experiences related to cancer were eligible for inclusion. Included articles were critically appraised using the Joanna Briggs Institute appraisal tool for qualitative studies, and thematic findings were meta-aggregated.
Results
The search identified 5632 articles; after screening, a total of 21 studies were included. During the meta-aggregation phase, 11 synthesised findings were identified: structural racism, biomedical health systems, colonisation, shame, fear, loneliness, spiritual pain, loneliness, gratitude, connection, strength and feeling all consumed.
Conclusion
There is a need to prioritise and involve Indigenous healthcare workers in all stages of the cancer experience to preserve traditional, cultural and spiritual ways of healing and to deliver culturally responsive healthcare for Indigenous patients.
心理肿瘤学是与癌症治疗相关的一个研究分支，关注癌症经历的心理、行为、精神、身体和社会方面。虽然心理肿瘤学及其应用是相对新生的，但关于土著社区的心理肿瘤学考虑的研究缺乏。由于殖民化的有害影响，土著人民的疾病负担比非土著人口高得不成比例。然而，缺乏对发展适当护理模式的重视未能反映这一点。因此，本系统综述旨在建立对全球土著人民心理肿瘤学的理解。方法两名独立审稿人采用预先设定的检索策略对PubMed、Embase、Web of Science、PsychInfo和ProQuest进行检索。搜索不受地理环境、语言、年龄或性别的限制。对土著参与者进行的关注与癌症有关的心理体验的定性研究符合纳入标准。使用乔安娜布里格斯研究所定性研究的评估工具对纳入的文章进行了批判性评估，并对专题研究结果进行了meta汇总。结果检索到5632篇文献；筛选后，共纳入21项研究。在元汇总阶段，确定了11项综合发现：结构性种族主义、生物医学卫生系统、殖民、羞耻、恐惧、孤独、精神痛苦、孤独、感激、联系、力量和感觉都被消耗掉了。有必要在癌症治疗的各个阶段优先考虑土著保健工作者，并让他们参与其中，以保留传统的、文化的和精神的治疗方式，并为土著病人提供符合文化要求的保健服务。
{"title":"A Qualitative Systematic Review of the Psycho-Oncological Experiences Amongst Global Indigenous Communities","authors":"Eda So, Brianna Poirier, Madison Cachagee, Joanne Hedges, Lisa Jamieson, Sneha Sethi","doi":"10.1155/ecc/3813657","DOIUrl":"https://doi.org/10.1155/ecc/3813657","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Psycho-oncology is a branch of research related to cancer care that focuses on the psychological, behavioural, spiritual, physical and social aspects of the cancer experience. Whilst psycho-oncology and its applications are relatively nascent, there is a paucity of research regarding the psycho-oncological considerations for Indigenous communities. Due to the deleterious impacts of colonisation, the burden of disease experienced amongst Indigenous Peoples is disproportionately higher than in non-Indigenous populations. Yet, the lack of attention paid towards the development of appropriate models of care fails to reflect this. Therefore, this systematic review aims to build an understanding of psycho-oncology for Indigenous Peoples, globally.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Two independent reviewers searched PubMed, Embase, Web of Science, PsychInfo and ProQuest using a pre-established search strategy. The search was not limited by geographic setting, language, age or gender. Qualitative studies with Indigenous participants that focused on the psychological experiences related to cancer were eligible for inclusion. Included articles were critically appraised using the Joanna Briggs Institute appraisal tool for qualitative studies, and thematic findings were meta-aggregated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The search identified 5632 articles; after screening, a total of 21 studies were included. During the meta-aggregation phase, 11 synthesised findings were identified: structural racism, biomedical health systems, colonisation, shame, fear, loneliness, spiritual pain, loneliness, gratitude, connection, strength and feeling all consumed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>There is a need to prioritise and involve Indigenous healthcare workers in all stages of the cancer experience to preserve traditional, cultural and spiritual ways of healing and to deliver culturally responsive healthcare for Indigenous patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11953,"journal":{"name":"European Journal of Cancer Care","volume":"2025 1","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/ecc/3813657","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145316961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Shima Heidari, Bita Shahrami, Soroush Rad, Mohammad Biglari, Rayeheh Tavajohi, Mohammad Vaezi
Background
Patients undergoing hematopoietic stem cell transplantation (HSCT) often face complications during the acute posttransplantation period. HSCT complications are linked to oxidative stress (OS) mechanisms due to accumulation of reactive oxygen species. Researchers hypothesize that antioxidant levels may modify OS immediately after HSCT.
Objective
This systematic review aimed to collect evidence on the role of antioxidant supplementation in determining the outcomes and complications of HSCT.
Study Design
A systematic search of two databases was conducted, including studies published until January 2024. Inclusion criteria involved clinical original studies focusing on adults and children undergoing HSCT who received antioxidant supplementation during and/or after HSCT.
Results
The review included 20 eligible studies, featuring antioxidants such as N-acetyl cysteine, vitamin C, zinc, selenium, vitamin E, and melatonin. Outcomes examined included immune system recovery, engraftment, oral mucositis, liver toxicity, nephrotoxicity, and acute graft-versus-host disease. The findings indicate an unclear association between antioxidant use and complications after HSCT. The certainty of evidence for these outcomes was low or very low.
Conclusions
Although the use of antioxidants in HSCT patients has been deemed safe and has even been associated with positive outcomes in some studies, the necessity for antioxidant supplementation during HSCT remains uncertain. Further large randomized controlled trials are necessary to ascertain antioxidant requirements and establish precise supplementation protocols for HSCT patients.
{"title":"The Role of Antioxidant Supplementation in Patients Undergoing Hematopoietic Stem Cell Transplantation: A Systematic Review","authors":"Shima Heidari, Bita Shahrami, Soroush Rad, Mohammad Biglari, Rayeheh Tavajohi, Mohammad Vaezi","doi":"10.1155/ecc/6414419","DOIUrl":"https://doi.org/10.1155/ecc/6414419","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Patients undergoing hematopoietic stem cell transplantation (HSCT) often face complications during the acute posttransplantation period. HSCT complications are linked to oxidative stress (OS) mechanisms due to accumulation of reactive oxygen species. Researchers hypothesize that antioxidant levels may modify OS immediately after HSCT.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This systematic review aimed to collect evidence on the role of antioxidant supplementation in determining the outcomes and complications of HSCT.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Study Design</h3>\u0000 \u0000 <p>A systematic search of two databases was conducted, including studies published until January 2024. Inclusion criteria involved clinical original studies focusing on adults and children undergoing HSCT who received antioxidant supplementation during and/or after HSCT.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The review included 20 eligible studies, featuring antioxidants such as N-acetyl cysteine, vitamin C, zinc, selenium, vitamin E, and melatonin. Outcomes examined included immune system recovery, engraftment, oral mucositis, liver toxicity, nephrotoxicity, and acute graft-versus-host disease. The findings indicate an unclear association between antioxidant use and complications after HSCT. The certainty of evidence for these outcomes was low or very low.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Although the use of antioxidants in HSCT patients has been deemed safe and has even been associated with positive outcomes in some studies, the necessity for antioxidant supplementation during HSCT remains uncertain. Further large randomized controlled trials are necessary to ascertain antioxidant requirements and establish precise supplementation protocols for HSCT patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11953,"journal":{"name":"European Journal of Cancer Care","volume":"2025 1","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/ecc/6414419","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145317028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The Cancer Functional Assessment Set (cFAS) is a comprehensive functional tool used to evaluate patients with cancer, and it has the potential to predict mortality with high accuracy. We investigated the accuracy of the cFAS for predicting mortality in hospitalized patients undergoing radiotherapy and/or chemotherapy for advanced cancer, and we calculated a clinically useful cutoff value of the cFAS.
Methods
Patients with advanced cancer undergoing chemotherapy and/or radiotherapy at our hospital were assessed using the cFAS at their admission, and their survival was followed. We plotted receiver operating characteristic (ROC) curves up to 365 days by using mortality data obtained every 30 days after study enrollment.
Results
The areas under the curve (AUCs) were 0.65–0.89 (max. value – min. value within the entire period), and the cutoff value for the cFAS was 66–79 points, calculated using the Youden index. The cutoff value’s sensitivity was 0.44–0.80, and its specificity was 0.76–0.93. The AUC showed a decrease after 150 days of follow-up.
Conclusions
The cFAS was able to predict mortality in patients with cancer undergoing chemotherapy and/or radiotherapy with moderate accuracy within approx. 150 days and with low accuracy thereafter up to 365 days.
{"title":"Accuracy of the Cancer Functional Assessment Set for Predicting Mortality in Patients With Advanced Cancer Undergoing Chemotherapy and/or Radiotherapy","authors":"Kenta Kawamura, Atsushi Tsukamoto, Kazuhiro Miyata, Kazuhide Tomita, Shinobu Minegishi","doi":"10.1155/ecc/8862225","DOIUrl":"https://doi.org/10.1155/ecc/8862225","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>The Cancer Functional Assessment Set (cFAS) is a comprehensive functional tool used to evaluate patients with cancer, and it has the potential to predict mortality with high accuracy. We investigated the accuracy of the cFAS for predicting mortality in hospitalized patients undergoing radiotherapy and/or chemotherapy for advanced cancer, and we calculated a clinically useful cutoff value of the cFAS.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Patients with advanced cancer undergoing chemotherapy and/or radiotherapy at our hospital were assessed using the cFAS at their admission, and their survival was followed. We plotted receiver operating characteristic (ROC) curves up to 365 days by using mortality data obtained every 30 days after study enrollment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The areas under the curve (AUCs) were 0.65–0.89 (max. value – min. value within the entire period), and the cutoff value for the cFAS was 66–79 points, calculated using the Youden index. The cutoff value’s sensitivity was 0.44–0.80, and its specificity was 0.76–0.93. The AUC showed a decrease after 150 days of follow-up.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The cFAS was able to predict mortality in patients with cancer undergoing chemotherapy and/or radiotherapy with moderate accuracy within approx. 150 days and with low accuracy thereafter up to 365 days.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11953,"journal":{"name":"European Journal of Cancer Care","volume":"2025 1","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/ecc/8862225","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145317027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
To examine factors associated with the self-efficacy for nutritional planning by family caregivers of patients with gastrointestinal (GI) cancer, with a focus on caregiver burden and decision-making related to the consumption of fruits and vegetables (F&V).
Methods
This cross-sectional study examined 378 family caregivers of patients who had GI cancers, mostly in the stomach, colorectum, or liver. Self-efficacy for nutrition planning, caregiver burden, and decision-making regarding the consumption of F&V were measured using the Nutrition Self-Efficacy Scale, the Brief Assessment Scale for Caregivers, and Henry’s Decisional Balance Scale for F&V consumption, respectively.
Results
Family caregivers who had greater nutritional self-efficacy had higher perceived “pros” regarding the health benefits of F&V, were married, had higher comorbidity scores, and had longer durations of caregiving. Family caregivers who had decreased nutritional self-efficacy had higher perceived “cons” to consuming F&V and increased perceived burden on other family members.
Conclusion
Our results suggest that increased awareness of the benefits and challenges of consuming F&V, along with strong support systems for family caregivers, can improve the diets of patients with GI cancer.
{"title":"Cross-Sectional Study of Factors Associated With Self-Efficacy for Nutritional Planning by Family Caregivers of Patients With Gastrointestinal Cancer","authors":"Myung Kyung Lee","doi":"10.1155/ecc/6497337","DOIUrl":"https://doi.org/10.1155/ecc/6497337","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To examine factors associated with the self-efficacy for nutritional planning by family caregivers of patients with gastrointestinal (GI) cancer, with a focus on caregiver burden and decision-making related to the consumption of fruits and vegetables (F&V).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This cross-sectional study examined 378 family caregivers of patients who had GI cancers, mostly in the stomach, colorectum, or liver. Self-efficacy for nutrition planning, caregiver burden, and decision-making regarding the consumption of F&V were measured using the Nutrition Self-Efficacy Scale, the Brief Assessment Scale for Caregivers, and Henry’s Decisional Balance Scale for F&V consumption, respectively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Family caregivers who had greater nutritional self-efficacy had higher perceived “pros” regarding the health benefits of F&V, were married, had higher comorbidity scores, and had longer durations of caregiving. Family caregivers who had decreased nutritional self-efficacy had higher perceived “cons” to consuming F&V and increased perceived burden on other family members.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Our results suggest that increased awareness of the benefits and challenges of consuming F&V, along with strong support systems for family caregivers, can improve the diets of patients with GI cancer.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11953,"journal":{"name":"European Journal of Cancer Care","volume":"2025 1","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/ecc/6497337","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145273012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Valentina Biagioli, Alessandro Inzoli, Antonella Barone, Alessandra Iurlo, Paola Guglielmelli, Francesca Palandri, Barbara Mora, Stefana Impera, Silvia Betti, Marco Santoro, Vittorio Rosti, Giovanni Barosi
Objective
This study aimed to develop and psychometrically test a self-report questionnaire for measuring self-care behaviors in patients with myeloproliferative neoplasms (MPNs): the Self-Care in MyeloProliferative Neoplasms Inventory (SC-MPNI).
Methods
A cross-sectional validation study was conducted in 9 Italian hematology centers from November 2021 to January 2024. Adult patients with myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) were asked to complete a paper-and-pencil questionnaire during their outpatient visit or at home. The SC-MPNI was developed according to the Middle-Range Theory of Self-Care of Chronic Illness. This 30-item questionnaire includes three scales: self-care maintenance, self-care monitoring, and self-care management. The construct validity was tested using confirmatory factor analysis (CFA). The reliability of each scale was evaluated using McDonald’s Omega composite reliability.
Results
Overall, 285 patients with MPNs (53% male; mean age = 60 years ± 13) were included. They were diagnosed with MF (43%), PV (29%), or ET (28%). The self-care maintenance scale (13 items and 3 factors: adherence, healthy lifestyle, and prevention) fit well when tested with a three-factor model, and its reliability was 0.87. The self-care monitoring scale (9 items and 2 factors: symptom monitoring and parameter and test monitoring) fit well when tested with a two-factor model, and its reliability was 0.85. The self-care management scale (8 items and 2 factors: provider-directed behaviors and spontaneous behaviors) fit well when tested with a two-factor model, and its reliability was 0.79.
Conclusion
The SC-MPNI is a valid and reliable self-report instrument to measure self-care behaviors in people living with MPNs.
{"title":"Validity and Reliability of the Self-Care in MyeloProliferative Neoplasms Inventory (SC-MPNI)","authors":"Valentina Biagioli, Alessandro Inzoli, Antonella Barone, Alessandra Iurlo, Paola Guglielmelli, Francesca Palandri, Barbara Mora, Stefana Impera, Silvia Betti, Marco Santoro, Vittorio Rosti, Giovanni Barosi","doi":"10.1155/ecc/8353115","DOIUrl":"https://doi.org/10.1155/ecc/8353115","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This study aimed to develop and psychometrically test a self-report questionnaire for measuring self-care behaviors in patients with myeloproliferative neoplasms (MPNs): the Self-Care in MyeloProliferative Neoplasms Inventory (SC-MPNI).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A cross-sectional validation study was conducted in 9 Italian hematology centers from November 2021 to January 2024. Adult patients with myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) were asked to complete a paper-and-pencil questionnaire during their outpatient visit or at home. The SC-MPNI was developed according to the Middle-Range Theory of Self-Care of Chronic Illness. This 30-item questionnaire includes three scales: self-care maintenance, self-care monitoring, and self-care management. The construct validity was tested using confirmatory factor analysis (CFA). The reliability of each scale was evaluated using McDonald’s Omega composite reliability.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Overall, 285 patients with MPNs (53% male; mean age = 60 years ± 13) were included. They were diagnosed with MF (43%), PV (29%), or ET (28%). The self-care maintenance scale (13 items and 3 factors: adherence, healthy lifestyle, and prevention) fit well when tested with a three-factor model, and its reliability was 0.87. The self-care monitoring scale (9 items and 2 factors: symptom monitoring and parameter and test monitoring) fit well when tested with a two-factor model, and its reliability was 0.85. The self-care management scale (8 items and 2 factors: provider-directed behaviors and spontaneous behaviors) fit well when tested with a two-factor model, and its reliability was 0.79.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The SC-MPNI is a valid and reliable self-report instrument to measure self-care behaviors in people living with MPNs.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11953,"journal":{"name":"European Journal of Cancer Care","volume":"2025 1","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/ecc/8353115","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145272631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Robert Knoerl, Emanuele Mazzola, Lindsay Frazier, Roy L. Freeman, Marilyn Hammer, Fangxin Hong, Ann LaCasce, Jennifer Ligibel, Marlise R. Luskin, Donna Berry
Purpose
The purpose of this secondary analysis was to explore paclitaxel-induced peripheral neuropathy severity patterns among women with breast cancer receiving weekly or dose dense paclitaxel regimens.
Methods
Young adult women with breast cancer (18–39 years) beginning cancer treatment with dose dense (175 mg/m2 every 14 days) or weekly (80 mg/m2) paclitaxel completed the QLQ-CIPN20 before the first paclitaxel infusion (T1) and then at two time points during paclitaxel chemotherapy (T2: 350 mg/m2 and T3: 700 mg/m2). QLQ-CIPN20 scores were compared between women receiving dose dense or weekly paclitaxel across the three time points using mixed-effect linear regression models.
Results
Among women receiving dose dense paclitaxel (n = 27), mean QLQ-CIPN4 scores increased from 4.63 at T1 to 15.43 at T3, while among women receiving weekly paclitaxel (n = 12), mean QLQ-CIPN4 scores increased from 2.08 at T1 to 5.56 at T3. Similar trends were observed for changes in QLQ-CIPN20 sensory and motor subscale scores among both groups. Overall, while CIPN severity was worse at each time point among women receiving dose dense paclitaxel relative to women receiving weekly paclitaxel, there were no statistically significant differences between groups for changes in QLQ-CIPN4 (p = 0.24), QLQ-CIPN20 sensory (p = 0.41), or QLQ-CIPN20 motor score (p = 0.68) over time.
Conclusions
The results may be used to promote awareness among patients and clinicians regarding potential trajectories of paclitaxel-induced peripheral neuropathy for women with breast cancer.
{"title":"Exploring Chemotherapy-Induced Peripheral Neuropathy Severity Patterns in Young Adult Women With Breast Cancer Receiving Weekly or Dose Dense Paclitaxel","authors":"Robert Knoerl, Emanuele Mazzola, Lindsay Frazier, Roy L. Freeman, Marilyn Hammer, Fangxin Hong, Ann LaCasce, Jennifer Ligibel, Marlise R. Luskin, Donna Berry","doi":"10.1155/ecc/4229814","DOIUrl":"https://doi.org/10.1155/ecc/4229814","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Purpose</h3>\u0000 \u0000 <p>The purpose of this secondary analysis was to explore paclitaxel-induced peripheral neuropathy severity patterns among women with breast cancer receiving weekly or dose dense paclitaxel regimens.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Young adult women with breast cancer (18–39 years) beginning cancer treatment with dose dense (175 mg/m<sup>2</sup> every 14 days) or weekly (80 mg/m<sup>2</sup>) paclitaxel completed the QLQ-CIPN20 before the first paclitaxel infusion (T1) and then at two time points during paclitaxel chemotherapy (T2: 350 mg/m<sup>2</sup> and T3: 700 mg/m<sup>2</sup>). QLQ-CIPN20 scores were compared between women receiving dose dense or weekly paclitaxel across the three time points using mixed-effect linear regression models.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among women receiving dose dense paclitaxel (<i>n</i> = 27), mean QLQ-CIPN4 scores increased from 4.63 at T1 to 15.43 at T3, while among women receiving weekly paclitaxel (<i>n</i> = 12), mean QLQ-CIPN4 scores increased from 2.08 at T1 to 5.56 at T3. Similar trends were observed for changes in QLQ-CIPN20 sensory and motor subscale scores among both groups. Overall, while CIPN severity was worse at each time point among women receiving dose dense paclitaxel relative to women receiving weekly paclitaxel, there were no statistically significant differences between groups for changes in QLQ-CIPN4 (<i>p</i> = 0.24), QLQ-CIPN20 sensory (<i>p</i> = 0.41), or QLQ-CIPN20 motor score (<i>p</i> = 0.68) over time.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The results may be used to promote awareness among patients and clinicians regarding potential trajectories of paclitaxel-induced peripheral neuropathy for women with breast cancer.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11953,"journal":{"name":"European Journal of Cancer Care","volume":"2025 1","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/ecc/4229814","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145272097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Asmaa Namoos, Nicholas Thomson, Carol Olson, Vanessa Sheppard, Michel Aboutanos
Background
Breast cancer survivors face a dual burden of physical and psychological challenges, which may persist long after treatment. This study aims to evaluate the physical impairments and psychological outcomes among breast cancer survivors compared to individuals without breast cancer.
Methods
We conducted a retrospective cohort study using data from 3650 breast cancer survivors and 145,280 individuals without breast cancer from the Virginia Commonwealth University Health System (VCUHS) between January 2024 and 2025. Data were extracted through the TriNetX platform using ICD-10 codes to identify relevant diagnoses and outcomes. Physical outcomes included abnormalities of gait and mobility, unsteadiness on feet, and falls. Psychological outcomes assessed were depression, stress-related disorders, and anxiety following falls. Risk differences, risk ratios (RR), and odds ratios with 95% confidence intervals (CIs) were calculated to compare outcomes between groups.
Results
Breast cancer survivors exhibited a higher risk of physical impairments compared to nonbreast cancer individuals. The risk of gait and mobility abnormalities was 2.725% in breast cancer survivors versus 1.741% in the comparison group (RR: 1.565; 95% CI: 1.285–1.906; p < 0.0001). Unsteadiness on feet was more prevalent among breast cancer survivors (0.817%) compared to 0.296% in non-cancer individuals (RR: 2.762; 95% CI: 1.91–3.993; p < 0.0001). Additionally, breast cancer survivors had a higher risk of falls (1.644%) compared to nonbreast cancer patients (1.081%) (RR: 1.521; 95% CI: 1.178–1.964; p = 0.0012). Psychologically, breast cancer survivors who experienced falls were more likely to suffer from depression (28.57% vs. 13.1%, p = 0.0002), stress-related disorders (14.29% vs. 3.49%, p < 0.0001), and anxiety (28.57% vs. 15.72%, p = 0.0040) compared to fallers without breast cancer.
Conclusion
Functional limitations such as unsteadiness and falls are significantly more common among breast cancer survivors and are strongly associated with psychological distress. These findings support mobility impairments as a potential pathway linking cancer treatment to adverse mental health outcomes. Future research should integrate structured ICD-10 data with unstructured oncology notes to enhance fall prediction models and guide personalized survivorship care.
乳腺癌幸存者面临着身体和心理的双重负担，这可能在治疗后很长一段时间内持续存在。本研究旨在评估乳腺癌幸存者与非乳腺癌个体相比的身体损伤和心理结果。方法：我们进行了一项回顾性队列研究，使用了2024年1月至2025年1月期间来自弗吉尼亚联邦大学卫生系统（VCUHS）的3650名乳腺癌幸存者和145280名非乳腺癌患者的数据。使用ICD-10代码通过TriNetX平台提取数据，以确定相关诊断和结果。身体结果包括步态和活动异常、脚不稳和跌倒。评估的心理结果包括抑郁、压力相关障碍和跌倒后的焦虑。计算风险差异、风险比（RR）和95%置信区间（ci）的优势比，比较两组间的结果。结果：与非乳腺癌个体相比，乳腺癌幸存者表现出更高的身体损伤风险。乳腺癌幸存者步态和活动异常的风险为2.725%，对照组为1.741% （RR: 1.565; 95% CI: 1.285-1.906; p < 0.0001）。脚不稳在乳腺癌幸存者中更为普遍（0.817%），而在非癌症个体中为0.296% （RR: 2.762; 95% CI: 1.91-3.993; p < 0.0001）。此外，乳腺癌幸存者摔倒的风险（1.644%）高于非乳腺癌患者（1.081%）（RR: 1.521; 95% CI: 1.178-1.964; p = 0.0012）。在心理上，与没有患乳腺癌的跌倒者相比，经历过跌倒的乳腺癌幸存者更容易患抑郁症（28.57%对13.1%,p = 0.0002）、压力相关疾病（14.29%对3.49%,p < 0.0001）和焦虑（28.57%对15.72%,p = 0.0040）。结论不稳、跌倒等功能障碍在乳腺癌幸存者中更为常见，并与心理困扰密切相关。这些发现支持活动障碍是将癌症治疗与不良心理健康结果联系起来的潜在途径。未来的研究应将结构化的ICD-10数据与非结构化的肿瘤学记录结合起来，以增强跌倒预测模型并指导个性化的生存护理。
{"title":"Physical and Psychological Burdens Among Breast Cancer Survivors: Evaluating Post-Treatment Gait Impairment, Falls, and Depression Using Real-World Data","authors":"Asmaa Namoos, Nicholas Thomson, Carol Olson, Vanessa Sheppard, Michel Aboutanos","doi":"10.1155/ecc/5558563","DOIUrl":"https://doi.org/10.1155/ecc/5558563","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Breast cancer survivors face a dual burden of physical and psychological challenges, which may persist long after treatment. This study aims to evaluate the physical impairments and psychological outcomes among breast cancer survivors compared to individuals without breast cancer.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted a retrospective cohort study using data from 3650 breast cancer survivors and 145,280 individuals without breast cancer from the Virginia Commonwealth University Health System (VCUHS) between January 2024 and 2025. Data were extracted through the TriNetX platform using ICD-10 codes to identify relevant diagnoses and outcomes. Physical outcomes included abnormalities of gait and mobility, unsteadiness on feet, and falls. Psychological outcomes assessed were depression, stress-related disorders, and anxiety following falls. Risk differences, risk ratios (RR), and odds ratios with 95% confidence intervals (CIs) were calculated to compare outcomes between groups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Breast cancer survivors exhibited a higher risk of physical impairments compared to nonbreast cancer individuals. The risk of gait and mobility abnormalities was 2.725% in breast cancer survivors versus 1.741% in the comparison group (RR: 1.565; 95% CI: 1.285–1.906; <i>p</i> < 0.0001). Unsteadiness on feet was more prevalent among breast cancer survivors (0.817%) compared to 0.296% in non-cancer individuals (RR: 2.762; 95% CI: 1.91–3.993; <i>p</i> < 0.0001). Additionally, breast cancer survivors had a higher risk of falls (1.644%) compared to nonbreast cancer patients (1.081%) (RR: 1.521; 95% CI: 1.178–1.964; <i>p</i> = 0.0012). Psychologically, breast cancer survivors who experienced falls were more likely to suffer from depression (28.57% vs. 13.1%, <i>p</i> = 0.0002), stress-related disorders (14.29% vs. 3.49%, <i>p</i> < 0.0001), and anxiety (28.57% vs. 15.72%, <i>p</i> = 0.0040) compared to fallers without breast cancer.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Functional limitations such as unsteadiness and falls are significantly more common among breast cancer survivors and are strongly associated with psychological distress. These findings support mobility impairments as a potential pathway linking cancer treatment to adverse mental health outcomes. Future research should integrate structured ICD-10 data with unstructured oncology notes to enhance fall prediction models and guide personalized survivorship care.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11953,"journal":{"name":"European Journal of Cancer Care","volume":"2025 1","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/ecc/5558563","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145271778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Manli Liu, Qingran Lin, Shuxian Zhang, Mei Feng, Guihong Wu
Background
This study aimed to evaluate the reliability of a self-administered oral nutritional supplement adherence assessment scale for patients with colorectal cancer.
Methods
A presurvey was conducted with 25 colorectal cancer patients already taking nutritional supplements, obtained using purposive sampling to assess the comprehensibility and linguistic expression of the scale items. Following this, 310 questionnaires were distributed during the main survey, with 303 validly returned, yielding a validity rate of 97.74%.
Results
The scale underwent linguistic debugging, resulting in a final version comprising 3 dimensions and 28 items. Exploratory factor analysis (EFA) demonstrated statistically significant KMO values ranging from 0.864 to 0.902 for the three dimensions (p < 0.001). Two common factors were extracted from the knowledge dimension, contributing to a cumulative variance of 66.22%. One common factor was extracted from the belief dimension, with a cumulative variance contribution of 66.29%. The behavior dimension also demonstrated a cumulative variance contribution of 61.78%. The scale exhibited a Cronbach’s α coefficient of 0.904, split-half reliability of 0.857, a retest reliability coefficient of 0.859, and a content validity index (S-CVI) of 0.903.
Conclusion
The developed oral nutritional supplement adherence assessment scale for colorectal cancer patients demonstrated strong reliability and validity, making it an effective tool for evaluating adherence to oral nutritional supplementation. This scale can serve as a reference for the future development of related assessment tools and may contribute to improving nutritional management and clinical outcomes for patients with colorectal cancer.
{"title":"Reliability Test of the Oral Nutritional Supplement Adherence Assessment Scale for Colorectal Cancer Patients","authors":"Manli Liu, Qingran Lin, Shuxian Zhang, Mei Feng, Guihong Wu","doi":"10.1155/ecc/8572726","DOIUrl":"https://doi.org/10.1155/ecc/8572726","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>This study aimed to evaluate the reliability of a self-administered oral nutritional supplement adherence assessment scale for patients with colorectal cancer.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A presurvey was conducted with 25 colorectal cancer patients already taking nutritional supplements, obtained using purposive sampling to assess the comprehensibility and linguistic expression of the scale items. Following this, 310 questionnaires were distributed during the main survey, with 303 validly returned, yielding a validity rate of 97.74%.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The scale underwent linguistic debugging, resulting in a final version comprising 3 dimensions and 28 items. Exploratory factor analysis (EFA) demonstrated statistically significant KMO values ranging from 0.864 to 0.902 for the three dimensions (<i>p</i> < 0.001). Two common factors were extracted from the knowledge dimension, contributing to a cumulative variance of 66.22%. One common factor was extracted from the belief dimension, with a cumulative variance contribution of 66.29%. The behavior dimension also demonstrated a cumulative variance contribution of 61.78%. The scale exhibited a Cronbach’s <i>α</i> coefficient of 0.904, split-half reliability of 0.857, a retest reliability coefficient of 0.859, and a content validity index (S-CVI) of 0.903.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The developed oral nutritional supplement adherence assessment scale for colorectal cancer patients demonstrated strong reliability and validity, making it an effective tool for evaluating adherence to oral nutritional supplementation. This scale can serve as a reference for the future development of related assessment tools and may contribute to improving nutritional management and clinical outcomes for patients with colorectal cancer.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11953,"journal":{"name":"European Journal of Cancer Care","volume":"2025 1","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/ecc/8572726","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145224015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号